Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
What is the future of organoid and assembloid regulation?
Four experts weigh in on how to establish ethical guardrails for research on the 3D neuron clusters as these models become ever more complex.
What is the future of organoid and assembloid regulation?
Four experts weigh in on how to establish ethical guardrails for research on the 3D neuron clusters as these models become ever more complex.
Insights on suicidality and autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 8 December.
Insights on suicidality and autism; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 8 December.
Exclusive: Springer Nature retracts, removes nearly 40 publications that trained neural networks on ‘bonkers’ dataset
The dataset contains images of children’s faces downloaded from websites about autism, which sparked concerns at Springer Nature about consent and reliability.
Exclusive: Springer Nature retracts, removes nearly 40 publications that trained neural networks on ‘bonkers’ dataset
The dataset contains images of children’s faces downloaded from websites about autism, which sparked concerns at Springer Nature about consent and reliability.